Burned by EU backtrack, Valneva flags talks with potential partner for next-gen COVID-19 shot By James Waldron Sep 26, 2022 9:25am Valneva COVID-19 Deals ...

AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply ...

PARIS (Reuters) -Valneva now expects a positive recommendation from the European Medicines Agency (EMA) in April for its VLA2001 COVID-19 candidate vaccine, the French vaccine maker said on Friday ...

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront ...

Valneva SE Sponsored ADR (VALN) shares ended the last trading session 17.4% higher at $7.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

France's Haute Autorite de Sante public health body advised the government not to use Valneva's VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products ...

Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the ...

Valneva plans to monitor the durability of the antibody response in a subset of participants for at least five years as part of a dedicated persistence trial. But, with top-line lot-to-lot ...

Valneva now also has longer-term immunogenicity data. After six months, 96.3% of the analyzed subjects had protective levels of CHIKV neutralizing antibodies.

Valneva also started to provide boosters to volunteers in its Phase 1/2 VLA2001-201 trial. The booster shot will be provided to each volunteer six months after the initial vaccination.

Debt Management: Valneva's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.12, the company relies more heavily on borrowed funds, indicating a higher level of ...

With that positive data, Valneva now looks to launch a phase 2 in the second half of 2018. It will be carried out in Lyme-endemic regions in the U.S. and Europe, and include subjects previously ...